Disease The intractable diseases designated by MHLW, Japan

Diseases : 348 - Clinical trials : 43,690 / Drugs : 27,527 - ( DrugBank : 2,441 ) / Drug target genes : 714 - Drug target pathways : 315

ID	Disease name [Group]	Clinical trial Phase 1 / 2 / 3 / 4	Drug [ DrugBank ]	Target gene Target pathway	Domestic patients Med expenses recipients, FY2024 (corrected)
1	Spinal and bulbar muscular atrophy [Neu] 💬 "Spinobulbar muscular atrophy", "SBMA", "Kennedy disease", "Kennedy syndrome", "Kennedy-Alter-Sung syndrome" 1. Spinal and bulbar muscular atrophy × [Neu] Neuromuscular diseases	20 trials    | 1 / 14 / 2 / 1 💬 1. Spinal and bulbar muscular atrophy × Some trials have no Phase data.	19 drugs   [ 8 drugs ]	11 genes   20 pathways	1,758 patients Age distribution💬 1. Spinal and bulbar muscular atrophy × Age Num 0-9 - 10-19 - 20-29 1 30-39 24 40-49 162 50-59 445 60-69 565 70-74 255 75- 306
2	Amyotrophic lateral sclerosis [Neu] 💬 "ALS" 2. Amyotrophic lateral sclerosis × [Neu] Neuromuscular diseases	867 trials    | 179 / 363 / 272 / 11 💬 2. Amyotrophic lateral sclerosis × Some trials have no Phase data.	820 drugs   [ 185 drugs ]	189 genes   237 pathways	9,769 patients Age distribution💬 2. Amyotrophic lateral sclerosis × Age Num 0-9 - 10-19 1 20-29 15 30-39 96 40-49 492 50-59 1,355 60-69 2,400 70-74 1,753 75- 3,657
3	Spinal muscular atrophy [Neu] 💬 "SMA", "Myelopathic muscular atrophy", "Werdnig-Hoffman disease", "Dubowitz disease", "Kugelberg-Welander disease", "Dubowitz syndrome" 3. Spinal muscular atrophy × [Neu] Neuromuscular diseases	317 trials    | 46 / 132 / 135 / 18 💬 3. Spinal muscular atrophy × Some trials have no Phase data.	217 drugs   [ 34 drugs ]	55 genes   79 pathways	943 patients Age distribution💬 3. Spinal muscular atrophy × Age Num 0-9 2 10-19 49 20-29 161 30-39 89 40-49 116 50-59 142 60-69 155 70-74 93 75- 136
4	Primary lateral sclerosis [Neu] 💬 "PLS" 4. Primary lateral sclerosis × [Neu] Neuromuscular diseases	7 trials    | 1 / 0 / 0 / 0 💬 4. Primary lateral sclerosis × Some trials have no Phase data.	20 drugs   [ 5 drugs ]	16 genes   28 pathways	182 patients Age distribution💬 4. Primary lateral sclerosis × Age Num 0-9 - 10-19 - 20-29 - 30-39 1 40-49 5 50-59 18 60-69 48 70-74 34 75- 76
5	Progressive supranuclear palsy [Neu] 💬 "PSP" 5. Progressive supranuclear palsy × [Neu] Neuromuscular diseases	120 trials    | 22 / 51 / 10 / 2 💬 5. Progressive supranuclear palsy × Some trials have no Phase data.	141 drugs   [ 36 drugs ]	68 genes   112 pathways	13,567 patients Age distribution💬 5. Progressive supranuclear palsy × Age Num 0-9 - 10-19 - 20-29 - 30-39 - 40-49 7 50-59 111 60-69 1,195 70-74 2,119 75- 10,135
6	Parkinson disease [Neu] 💬 "Disease Parkinson's", "Parkinson syndrome", "Parkinsonian syndrome" 6. Parkinson disease × [Neu] Neuromuscular diseases	2,817 trials    | 400 / 771 / 613 / 242 💬 6. Parkinson disease × Some trials have no Phase data.	2,606 drugs   [ 348 drugs ]	185 genes   205 pathways	150,576 patients Age distribution💬 6. Parkinson disease × Age Num 0-9 - 10-19 2 20-29 24 30-39 122 40-49 1,006 50-59 5,869 60-69 20,056 70-74 24,052 75- 99,445
7	Corticobasal degeneration [Neu] 💬 "Corticobasal syndrome", "CBD" 7. Corticobasal degeneration × [Neu] Neuromuscular diseases	28 trials    | 1 / 2 / 0 / 0 💬 7. Corticobasal degeneration × Some trials have no Phase data.	55 drugs   [ 14 drugs ]	9 genes   42 pathways	4,462 patients Age distribution💬 7. Corticobasal degeneration × Age Num 0-9 - 10-19 - 20-29 - 30-39 1 40-49 14 50-59 116 60-69 614 70-74 815 75- 2,902
8	Huntington disease [Neu] 💬 "Huntington chorea", "Huntington syndrome" 8. Huntington disease × [Neu] Neuromuscular diseases	296 trials    | 75 / 159 / 52 / 5 💬 8. Huntington disease × Some trials have no Phase data.	245 drugs   [ 63 drugs ]	89 genes   165 pathways	860 patients Age distribution💬 8. Huntington disease × Age Num 0-9 - 10-19 1 20-29 7 30-39 31 40-49 113 50-59 225 60-69 213 70-74 97 75- 173
9	Neuroacanthocytosis [Neu] 💬 "Choreoacanthocytosis", "Chorea-acanthocytosis", "Levine-Critchley syndrome", "McLeod syndrome", "Huntington disease-like 2", "HDL2" 9. Neuroacanthocytosis × [Neu] Neuromuscular diseases	-	-	-	32 patients Age distribution💬 9. Neuroacanthocytosis × Age Num 0-9 - 10-19 - 20-29 - 30-39 6 40-49 10 50-59 9 60-69 3 70-74 3 75- 1
10	Charcot-Marie-Tooth disease [Neu] 💬 "CMT" 10. Charcot-Marie-Tooth disease × [Neu] Neuromuscular diseases	59 trials    | 11 / 20 / 24 / 0 💬 10. Charcot-Marie-Tooth disease × Some trials have no Phase data.	76 drugs   [ 12 drugs ]	13 genes   24 pathways	1,009 patients Age distribution💬 10. Charcot-Marie-Tooth disease × Age Num 0-9 1 10-19 10 20-29 59 30-39 47 40-49 128 50-59 200 60-69 231 70-74 113 75- 220
11	Myasthenia gravis [Neu] 💬 "MG" 11. Myasthenia gravis × [Neu] Neuromuscular diseases	525 trials    | 29 / 129 / 289 / 24 💬 11. Myasthenia gravis × Some trials have no Phase data.	355 drugs   [ 80 drugs ]	75 genes   139 pathways	28,324 patients Age distribution💬 11. Myasthenia gravis × Age Num 0-9 1 10-19 86 20-29 537 30-39 1,175 40-49 2,523 50-59 4,808 60-69 5,784 70-74 3,756 75- 9,654
12	Congenital myasthenic syndrome [Neu] 💬 "End-plate acetylcholine receptor deficiency", "Slow-channel congenital myasthenic syndrome", "Fast-channel congenital myasthenic syndrome", "Sodium channel myasthenia", "End-plate acetylcholine esterase deficiency", "Congenital myasthenic syndrome with episodic apnoea", "Dok-7 myasthenia", "DOK7 congenital myasthenic syndrome" 12. Congenital myasthenic syndrome × [Neu] Neuromuscular diseases	7 trials    | 3 / 0 / 0 / 0 💬 12. Congenital myasthenic syndrome × Some trials have no Phase data.	8 drugs   [ 3 drugs ]	8 genes   16 pathways	18 patients Age distribution💬 12. Congenital myasthenic syndrome × Age Num 0-9 4 10-19 1 20-29 2 30-39 7 40-49 3 50-59 - 60-69 1 70-74 - 75- -
13	Multiple sclerosis/Neuromyelitis optica [Neu] 💬 "Multiple sclerosis", "Neuromyelitis optica", "Neuromyelitis optica spectrum disorder", "NMOSD", "Balo concentric sclerosis", "Baló concentric sclerosis" 13. Multiple sclerosis/Neuromyelitis optica × [Neu] Neuromuscular diseases	3,898 trials    | 279 / 776 / 1367 / 423 💬 13. Multiple sclerosis/Neuromyelitis optica × Some trials have no Phase data.	2,785 drugs   [ 360 drugs ]	265 genes   239 pathways	25,200 patients Age distribution💬 13. Multiple sclerosis/Neuromyelitis optica × Age Num 0-9 - 10-19 68 20-29 1,289 30-39 3,214 40-49 5,931 50-59 7,135 60-69 4,105 70-74 1,457 75- 2,001
14	Chronic inflammatory demyelinating polyneuropathy [Neu] 💬 "Chronic inflammatory demyelinating polyradiculoneuropathy", "CIDP", "Multifocal motor neuropathy" 14. Chronic inflammatory demyelinating polyneuropathy × [Neu] Neuromuscular diseases	302 trials    | 3 / 130 / 132 / 11 💬 14. Chronic inflammatory demyelinating polyneuropathy × Some trials have no Phase data.	231 drugs   [ 32 drugs ]	16 genes   67 pathways	5,640 patients Age distribution💬 14. Chronic inflammatory demyelinating polyneuropathy × Age Num 0-9 - 10-19 11 20-29 155 30-39 250 40-49 612 50-59 1,046 60-69 1,228 70-74 690 75- 1,648
15	Inclusion body myositis [Neu] 💬 15. Inclusion body myositis × [Neu] Neuromuscular diseases	49 trials    | 6 / 18 / 24 / 0 💬 15. Inclusion body myositis × Some trials have no Phase data.	73 drugs   [ 19 drugs ]	14 genes   134 pathways	937 patients Age distribution💬 15. Inclusion body myositis × Age Num 0-9 - 10-19 - 20-29 - 30-39 - 40-49 11 50-59 67 60-69 206 70-74 174 75- 479
16	Crow-Fukase syndrome [Neu] 💬 "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "POEMS syndrome", "Takatsuki disease", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome", "PEP syndrome" 16. Crow-Fukase syndrome × [Neu] Neuromuscular diseases	19 trials    | 1 / 11 / 2 / 1 💬 16. Crow-Fukase syndrome × Some trials have no Phase data.	24 drugs   [ 11 drugs ]	6 genes   83 pathways	281 patients Age distribution💬 16. Crow-Fukase syndrome × Age Num 0-9 - 10-19 - 20-29 1 30-39 8 40-49 37 50-59 65 60-69 74 70-74 41 75- 55
17	Multiple system atrophy [Neu] 💬 "MSA", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome" 17. Multiple system atrophy × [Neu] Neuromuscular diseases	171 trials    | 14 / 48 / 18 / 0 💬 17. Multiple system atrophy × Some trials have no Phase data.	202 drugs   [ 51 drugs ]	58 genes   114 pathways	10,170 patients Age distribution💬 17. Multiple system atrophy × Age Num 0-9 - 10-19 - 20-29 - 30-39 7 40-49 162 50-59 1,260 60-69 2,820 70-74 1,980 75- 3,941
18	Spinocerebellar degeneration [Neu] 💬 "SCD", "Spinocerebellar ataxia", "SCA", "Machado-Joseph disease", "MJD", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysian atrophy", "DRPLA", "Naito-Koyanagi disease", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EAOH", "Ataxia with vitamin E deficiency", "AVED", "Aprataxin deficiency", "APTX deficiency", "Friedreich ataxia", "FRDA", "Senataxin deficiency", "SETX deficiency", "Autosomal recessive spastic ataxia of Charlevoix-Saguenay", "Spastic ataxia" 18. Spinocerebellar degeneration × [Neu] Neuromuscular diseases	144 trials    | 27 / 63 / 32 / 4 💬 18. Spinocerebellar degeneration × Some trials have no Phase data.	174 drugs   [ 40 drugs ]	50 genes   75 pathways	26,493 patients Age distribution💬 18. Spinocerebellar degeneration × Age Num 0-9 - 10-19 18 20-29 320 30-39 844 40-49 1,830 50-59 3,683 60-69 5,357 70-74 3,899 75- 10,542
22	Moyamoya disease [Neu] 💬 "Occlusive disease in circle of Willis" 22. Moyamoya disease × [Neu] Neuromuscular diseases	36 trials    | 8 / 3 / 1 / 5 💬 22. Moyamoya disease × Some trials have no Phase data.	44 drugs   [ 26 drugs ]	36 genes   37 pathways	13,916 patients Age distribution💬 22. Moyamoya disease × Age Num 0-9 8 10-19 169 20-29 860 30-39 1,528 40-49 2,963 50-59 4,186 60-69 2,323 70-74 820 75- 1,059
23	Prion disease [Neu] 💬 "Creutzfeldt-Jakob disease", "CJD", "Sporadic CJD", "sCJD", "Gerstmann-Straussler-Scheinker syndrome", "GSS", "Fatal familial insomnia", "FFI", "Kuru disease", "Iatrogenic CJD", "iCJD", "Variant CCJD", "vCJD" 23. Prion disease × [Neu] Neuromuscular diseases	8 trials    | 2 / 2 / 2 / 0 💬 23. Prion disease × Some trials have no Phase data.	13 drugs   [ 3 drugs ]	-	443 patients Age distribution💬 23. Prion disease × Age Num 0-9 - 10-19 - 20-29 - 30-39 4 40-49 10 50-59 42 60-69 99 70-74 68 75- 220
24	Subacute sclerosing panencephalitis [Neu] 💬 "SSPE" 24. Subacute sclerosing panencephalitis × [Neu] Neuromuscular diseases	-	-	-	46 patients Age distribution💬 24. Subacute sclerosing panencephalitis × Age Num 0-9 - 10-19 - 20-29 11 30-39 26 40-49 8 50-59 - 60-69 - 70-74 1 75- -
25	Progressive multifocal leukoencephalopathy [Neu] 💬 "PML", "Leukoencephalopathy, progressive multifocal" 25. Progressive multifocal leukoencephalopathy × [Neu] Neuromuscular diseases	31 trials    | 1 / 11 / 1 / 1 💬 25. Progressive multifocal leukoencephalopathy × Some trials have no Phase data.	42 drugs   [ 23 drugs ]	7 genes   37 pathways	91 patients Age distribution💬 25. Progressive multifocal leukoencephalopathy × Age Num 0-9 - 10-19 - 20-29 2 30-39 1 40-49 13 50-59 15 60-69 21 70-74 18 75- 21
26	HTLV-1-associated myelopathy [Neu] 💬 "Tropical spastic paraparesis", "HTLV-1", "HTLV-I", "HAM" 26. HTLV-1-associated myelopathy × [Neu] Neuromuscular diseases	33 trials    | 8 / 17 / 9 / 3 💬 26. HTLV-1-associated myelopathy × Some trials have no Phase data.	60 drugs   [ 31 drugs ]	33 genes   113 pathways	1,042 patients Age distribution💬 26. HTLV-1-associated myelopathy × Age Num 0-9 - 10-19 - 20-29 - 30-39 11 40-49 21 50-59 93 60-69 260 70-74 200 75- 457
27	Idiopathic basal ganglia calcification [Neu] 💬 "IBGC", "Familial IBGC", "FIBGC", "Primary familial brain calcification", "PFBC", "Fahr disease" 27. Idiopathic basal ganglia calcification × [Neu] Neuromuscular diseases	2 trials    | 0 / 2 / 0 / 0 💬 27. Idiopathic basal ganglia calcification × Some trials have no Phase data.	1 drug   [ - ]	-	152 patients Age distribution💬 27. Idiopathic basal ganglia calcification × Age Num 0-9 - 10-19 - 20-29 2 30-39 5 40-49 14 50-59 20 60-69 33 70-74 27 75- 51
29	Ullrich disease [Neu] 💬 "Ullrich congenital muscular dystrophy", "Collagen VI-related myopathy" 29. Ullrich disease × [Neu] Neuromuscular diseases	-	-	-	23 patients Age distribution💬 29. Ullrich disease × Age Num 0-9 - 10-19 1 20-29 11 30-39 8 40-49 2 50-59 1 60-69 - 70-74 - 75- -
30	Distal myopathy [Neu] 💬 "Distal muscular dystrophy", "Miyoshi myopathy", "Distal dysferlinopathy", "Distal myopathy with rimmed vacuoles", "DMRV/GNE myopathy", "Oculopharyngodistal myopathy" 30. Distal myopathy × [Neu] Neuromuscular diseases	13 trials    | 1 / 3 / 10 / 0 💬 30. Distal myopathy × Some trials have no Phase data.	16 drugs   [ 2 drugs ]	1 gene   1 pathway	404 patients Age distribution💬 30. Distal myopathy × Age Num 0-9 - 10-19 1 20-29 14 30-39 40 40-49 74 50-59 107 60-69 84 70-74 31 75- 53
31	Bethlem myopathy [Neu] 💬 "Beth Rem myopathy" 31. Bethlem myopathy × [Neu] Neuromuscular diseases	-	-	-	26 patients Age distribution💬 31. Bethlem myopathy × Age Num 0-9 - 10-19 - 20-29 4 30-39 1 40-49 5 50-59 6 60-69 6 70-74 1 75- 3
32	Autophagic vacuolar myopathy [Neu] 💬 "Danon disease", "Danon syndrome", "X-linked myopathy with excessive autophagy", "XMEA" 32. Autophagic vacuolar myopathy × [Neu] Neuromuscular diseases	2 trials    | 1 / 1 / 0 / 0 💬 32. Autophagic vacuolar myopathy × Some trials have no Phase data.	2 drugs   [ 1 drug ]	-	10 patients Age distribution💬 32. Autophagic vacuolar myopathy × Age Num 0-9 - 10-19 - 20-29 1 30-39 2 40-49 1 50-59 2 60-69 2 70-74 - 75- 2
33	Schwartz-Jampel syndrome [Neu] 💬 "Schwarz-Yanperu syndrome", "SJS", "Myotonic chondrodystrophy", "Cartilage dystrophic myotonia", "Stuve-Wiedemann syndrome", "Stüve-Wiedemann syndrome" 33. Schwartz-Jampel syndrome × [Neu] Neuromuscular diseases	-	-	-	1 patient Age distribution💬 33. Schwartz-Jampel syndrome × Age Num 0-9 - 10-19 - 20-29 - 30-39 - 40-49 - 50-59 - 60-69 1 70-74 - 75- -
111	Congenital myopathy [Neu] 💬 "Nemaline myopathy", "Central core disease", "Minicore myopathy", "Multi-minicore myopathy", "Multi-minicore disease", "Myotubular myopathy", "X-linked myotubular myopathy", "XLMTM", "Centronuclear myopathy", "CNM", "Congenital fiber-type disproportion myopathy", "Congenital fiber-type disproportion" 111. Congenital myopathy × [Neu] Neuromuscular diseases	13 trials    | 7 / 9 / 2 / 1 💬 111. Congenital myopathy × Some trials have no Phase data.	37 drugs   [ 7 drugs ]	2 genes   53 pathways	405 patients Age distribution💬 111. Congenital myopathy × Age Num 0-9 1 10-19 10 20-29 85 30-39 47 40-49 75 50-59 73 60-69 60 70-74 27 75- 27
112	Marinesco-Sjogren syndrome [Neu] 💬 "Hereditary cerebellar ataxia-childhood cataracts" 112. Marinesco-Sjogren syndrome × [Neu] Neuromuscular diseases	-	-	-	6 patients Age distribution💬 112. Marinesco-Sjogren syndrome × Age Num 0-9 - 10-19 - 20-29 2 30-39 1 40-49 1 50-59 1 60-69 1 70-74 - 75- -
113	Muscular dystrophy [Neu] 💬 "Dystrophinopathies", "Duchenne muscular dystrophy", "DMD", "Becker muscular dystrophy", "BMD", "Limb-girdle muscular dystrophy", "LGMD", "Congenital muscular dystrophy", "CMD", "Fukuyama-type congenital muscular dystrophy", "FCMD", "Walker-Warburg syndrome", "WWS", "Muscle-Eye-Brain disease", "MEB disease", "α-dystroglycanopathy", "Integrin α7 deficient CMD", "CIntegrin α7 deficient ongenital muscular dystrophy", "Merosin-deficient congenital muscular dystrophy", "Ullrich congenital muscular dystrophy", "Laminopathy", "Rigid spine syndrome", "Dynamin 2 deficient congenital muscular dystrophy", "Telesonin-deficient congenital muscular dystrophy", "Congenital muscular dystrophy with mitochondrial structural abnormalities", "Facioscapulohumeral muscular dystrophy", "FSMD", "Myotonic dystrophy", "Dystrophia myotonica", "DM", "Emery-Dreifuss muscular dystrophy", "EDMD", "Oculopharyngeal muscular dystrophy", "OPMD", "Myotilinopathy", "Caveolinopathy", "Limb gridle muscular dystrophy 1C", "LGMD1C", "Desminopathy", "Sarcoglycanopathy" 113. Muscular dystrophy × [Neu] Neuromuscular diseases	826 trials    | 184 / 318 / 292 / 11 💬 113. Muscular dystrophy × Some trials have no Phase data.	680 drugs   [ 126 drugs ]	86 genes   188 pathways	5,920 patients Age distribution💬 113. Muscular dystrophy × Age Num 0-9 10 10-19 49 20-29 641 30-39 750 40-49 1,299 50-59 1,658 60-69 913 70-74 273 75- 327
114	Non-dystrophic myotonia syndrome [Neu] 💬 "Non-dystrophic Myotonia", "Myotonia congenita", "Thomsen disease", "Thomsen syndrome", "Autosomal-dominant myotonia congenita", "Becker disease", "Becker syndrome", "Autosomal-recessive myotonia congenita", "Paramyotonia congenita", "Sodium channel myotonia" 114. Non-dystrophic myotonia syndrome × [Neu] Neuromuscular diseases	13 trials    | 0 / 3 / 4 / 0 💬 114. Non-dystrophic myotonia syndrome × Some trials have no Phase data.	17 drugs   [ 3 drugs ]	6 genes   5 pathways	34 patients Age distribution💬 114. Non-dystrophic myotonia syndrome × Age Num 0-9 1 10-19 4 20-29 3 30-39 5 40-49 6 50-59 7 60-69 4 70-74 4 75- -
115	Hereditary periodic paralysis [Neu] 💬 "Periodic paralysis", "Hereditary hypokalemic periodic paralysis", "Andersen-Tawil syndrome", "Hereditary hyperkalemic periodic paralysis" 115. Hereditary periodic paralysis × [Neu] Neuromuscular diseases	11 trials    | 1 / 3 / 2 / 1 💬 115. Hereditary periodic paralysis × Some trials have no Phase data.	20 drugs   [ 7 drugs ]	20 genes   13 pathways	77 patients Age distribution💬 115. Hereditary periodic paralysis × Age Num 0-9 - 10-19 7 20-29 20 30-39 17 40-49 14 50-59 13 60-69 4 70-74 1 75- 1
116	Atopic myelitis [Neu] 💬 "Idiopathic eosinophilic myelitis" 116. Atopic myelitis × [Neu] Neuromuscular diseases	-	-	-	66 patients Age distribution💬 116. Atopic myelitis × Age Num 0-9 - 10-19 - 20-29 4 30-39 9 40-49 15 50-59 21 60-69 11 70-74 3 75- 3
117	Syringomyelia [Neu] 💬 117. Syringomyelia × [Neu] Neuromuscular diseases	5 trials    | 1 / 4 / 0 / 0 💬 117. Syringomyelia × Some trials have no Phase data.	7 drugs   [ 2 drugs ]	1 gene   66 pathways	647 patients Age distribution💬 117. Syringomyelia × Age Num 0-9 2 10-19 16 20-29 39 30-39 52 40-49 103 50-59 142 60-69 119 70-74 65 75- 109
118	Myelomeningocele [Neu] 💬 "Myeloschisis", "Myelocele", "Myelocystocele", "Syringomyelocele", "Neural tube defects" 118. Myelomeningocele × [Neu] Neuromuscular diseases	18 trials    | 2 / 2 / 2 / 1 💬 118. Myelomeningocele × Some trials have no Phase data.	34 drugs   [ 12 drugs ]	13 genes   53 pathways	177 patients Age distribution💬 118. Myelomeningocele × Age Num 0-9 5 10-19 6 20-29 121 30-39 21 40-49 11 50-59 10 60-69 2 70-74 - 75- 1
119	Isaacs syndrome [Neu] 💬 "Morvan syndrome", "Morvan fibrillary chorea", "Anti-VGKC antibody-associated limbic encephalitis" 119. Isaacs syndrome × [Neu] Neuromuscular diseases	-	-	-	118 patients Age distribution💬 119. Isaacs syndrome × Age Num 0-9 - 10-19 1 20-29 6 30-39 9 40-49 16 50-59 28 60-69 21 70-74 16 75- 21
120	Hereditary dystonia [Neu] 💬 "Primary dystonia", "X-linked dystonia parkinsonism", "Lubag", "Segawa syndrome", "SS", "Dopa-responsive dystonia", "DRD", "Paroxysmal nonkinesigenic dyskinesia 1", "PNKD1", "Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity", "Paroxysmal choreoathetosis and episodic ataxia and spasticity", "CSE", "Episodic kinesigenic dyskinesia 1", "EKD1", "Myoclonus-dystonia syndrome", "MDS", "Rapid-onset dystonia-parkinsonism", "RDP", "Alternating hemiplegia of childhood", "AHC", "Cerebellar ataxia, areflexia, pes cavus, optic atropy, and sensorineural hearing loss", "CAPOS", "Paroxysmal execise-induced dyskinesia", "PED", "Episodic kinesigenic dyskinesia 2", "EKD2", "Paroxysmal nonkinesigenic dyskinesia 2", "PNKD2", "MEPAN syndrome" 120. Hereditary dystonia × [Neu] Neuromuscular diseases	5 trials    | 1 / 0 / 0 / 0 💬 120. Hereditary dystonia × Some trials have no Phase data.	6 drugs   [ 3 drugs ]	17 genes   26 pathways	148 patients Age distribution💬 120. Hereditary dystonia × Age Num 0-9 - 10-19 7 20-29 42 30-39 28 40-49 29 50-59 19 60-69 18 70-74 5 75- -
121	Neurodegeneration with brain iron accumulation [Neu] 💬 "NBIA", "Neuroferritinopathy", "FTL", "NBIA3", "Pantothenate kinase-associated neurodegeneration", "PKAN", "NBIA1", "Infantile neuroaxonal dystrophy", "INAD", "NBIA2", "Calcium-independent phospholipase A2 group VI (PLA2G6) associated neurodegeneration", "PLAN", "NBIA/DYT/PARK-PLA2G6", "Neuroferritinopathy", "FTL", "NBIA3", "Mitochondrial membrane protein-associated neurodegeneration", "MPAN", "NBIA4", "Static encephalopathy of childhood with neurodegeneration in adulthood", "Beta-propeller protein-associated neurodegeneration", "BPAN", "NBIA5", "Coenzyme A synthase (COASY) protein-associated neurodegeneration", "CoPAN", "NBIA6", "Aceruloplaminemia", "Hereditary ceruloplasmin deficiency", "Fatty Acid Hydroxylase-associated neurodegeneration", "FAHN", "Dysmyelinating leukodystrophy and spastic paraparesis with or without dystonia、 spastic paraplegia 35", "Kufor-Rakeb syndrome", "KRS", "Woodhouse-Sakati syndrome", "DDB1 and CLUL4 associated factor 17", "DCAF17", "Hypogonadism, alopecia, diabetes mellitus, intellectual disability, and extrapyramidal syndrome" 121. Neurodegeneration with brain iron accumulation × [Neu] Neuromuscular diseases	30 trials    | 1 / 3 / 18 / 1 💬 121. Neurodegeneration with brain iron accumulation × Some trials have no Phase data.	31 drugs   [ 4 drugs ]	4 genes   109 pathways	14 patients Age distribution💬 121. Neurodegeneration with brain iron accumulation × Age Num 0-9 - 10-19 - 20-29 4 30-39 4 40-49 1 50-59 3 60-69 - 70-74 1 75- 1
122	Superficial siderosis [Neu] 💬 "SS", "Classical superficial siderosis", "Classical SS", "Brain table hemosiderosis" 122. Superficial siderosis × [Neu] Neuromuscular diseases	4 trials    | 0 / 0 / 0 / 0 💬 122. Superficial siderosis × Some trials have no Phase data.	8 drugs   [ 2 drugs ]	-	254 patients Age distribution💬 122. Superficial siderosis × Age Num 0-9 - 10-19 - 20-29 - 30-39 1 40-49 7 50-59 30 60-69 52 70-74 45 75- 119
123	Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy [Neu] 💬 "CARASIL", "Cerebral autosomal recessive arteriopathy with baldness and degenerative spondylosis", "Autosomal recessive leukoencephalopathy with baldness and degenerative spondylosis", "Cerebral autosomal recessive arteriopathy", "Autosomal recessive leukoencephalopathy", "HTRA1-related cerebral small vessel disease", "HRSVD" 123. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy × [Neu] Neuromuscular diseases	-	-	-	14 patients Age distribution💬 123. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy × Age Num 0-9 - 10-19 - 20-29 - 30-39 1 40-49 3 50-59 6 60-69 3 70-74 - 75- 1
124	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [Neu] 💬 "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease" 124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy × [Neu] Neuromuscular diseases	19 trials    | 1 / 11 / 0 / 0 💬 124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy × Some trials have no Phase data.	24 drugs   [ 11 drugs ]	6 genes   24 pathways	282 patients Age distribution💬 124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy × Age Num 0-9 - 10-19 - 20-29 - 30-39 2 40-49 29 50-59 84 60-69 97 70-74 44 75- 26
125	Hereditary diffuse leukoencephalopathy with spheroid [Neu] 💬 "HDLS", "Hereditary diffuse leukoencephalopathy" 125. Hereditary diffuse leukoencephalopathy with spheroid × [Neu] Neuromuscular diseases	1 trial    | 0 / 0 / 0 / 0 💬 125. Hereditary diffuse leukoencephalopathy with spheroid × Some trials have no Phase data.	8 drugs   [ - ]	-	78 patients Age distribution💬 125. Hereditary diffuse leukoencephalopathy with spheroid × Age Num 0-9 - 10-19 - 20-29 - 30-39 9 40-49 24 50-59 32 60-69 7 70-74 3 75- 3
126	Perry disease [Neu] 💬 "Perry syndrome" 126. Perry disease × [Neu] Neuromuscular diseases	-	-	-	4 patients Age distribution💬 126. Perry disease × Age Num 0-9 - 10-19 - 20-29 - 30-39 - 40-49 - 50-59 3 60-69 1 70-74 - 75- -
127	Frontotemporal lobar degeneration [Neu] 💬 "Frontotemporal dementia, behavioral abnormal type", "Frontotemporal dementia", "Semantic dementia" 127. Frontotemporal lobar degeneration × [Neu] Neuromuscular diseases	137 trials    | 25 / 49 / 30 / 6 💬 127. Frontotemporal lobar degeneration × Some trials have no Phase data.	175 drugs   [ 35 drugs ]	44 genes   112 pathways	1,513 patients Age distribution💬 127. Frontotemporal lobar degeneration × Age Num 0-9 - 10-19 - 20-29 1 30-39 7 40-49 17 50-59 151 60-69 614 70-74 370 75- 353
128	Bickerstaff brainstem encephalitis [Neu] 💬 128. Bickerstaff brainstem encephalitis × [Neu] Neuromuscular diseases	-	-	-	153 patients Age distribution💬 128. Bickerstaff brainstem encephalitis × Age Num 0-9 1 10-19 2 20-29 7 30-39 17 40-49 27 50-59 39 60-69 31 70-74 14 75- 15
129	Acute encephalopathy with biphasic seizures and late reduced diffusion [Neu] 💬 "AESD", "Epilepticus type biphasic acute encphalopathy", "Epilepticus type acute encphalopathy" 129. Acute encephalopathy with biphasic seizures and late reduced diffusion × [Neu] Neuromuscular diseases	2 trials    | 0 / 2 / 1 / 0 💬 129. Acute encephalopathy with biphasic seizures and late reduced diffusion × Some trials have no Phase data.	1 drug   [ 1 drug ]	-	48 patients Age distribution💬 129. Acute encephalopathy with biphasic seizures and late reduced diffusion × Age Num 0-9 9 10-19 19 20-29 20 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
130	Congenital insensitivity to pain with anhydrosis [Neu] 💬 "CIPA", "Congenital pain insensitivity with anhidrosis", "Hereditary sensory and autonomic neuropathy type IV", "HSAN4", "Hereditary sensory and autonomic neuropathy type V", "HSAN5" 130. Congenital insensitivity to pain with anhydrosis × [Neu] Neuromuscular diseases	-	-	-	45 patients Age distribution💬 130. Congenital insensitivity to pain with anhydrosis × Age Num 0-9 - 10-19 5 20-29 20 30-39 12 40-49 4 50-59 1 60-69 1 70-74 - 75- 2
131	Alexander disease [Neu] 💬 "ALXDRD", "AxD" 131. Alexander disease × [Neu] Neuromuscular diseases	5 trials    | 3 / 3 / 4 / 0 💬 131. Alexander disease × Some trials have no Phase data.	6 drugs   [ 2 drugs ]	-	55 patients Age distribution💬 131. Alexander disease × Age Num 0-9 - 10-19 - 20-29 8 30-39 4 40-49 6 50-59 11 60-69 11 70-74 4 75- 11
132	Congenital supranuclear bulbar palsy [Neu] 💬 "Congenital suprabulbar paresis", "Worcester drought syndrome", "Worster-Drought syndrome" 132. Congenital supranuclear bulbar palsy × [Neu] Neuromuscular diseases	-	-	-	7 patients Age distribution💬 132. Congenital supranuclear bulbar palsy × Age Num 0-9 5 10-19 2 20-29 - 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
133	Moebius syndrome [Neu] 💬 "Mobius syndrome", "Möbius syndrome" 133. Moebius syndrome × [Neu] Neuromuscular diseases	-	-	-	16 patients Age distribution💬 133. Moebius syndrome × Age Num 0-9 5 10-19 2 20-29 4 30-39 3 40-49 2 50-59 - 60-69 - 70-74 - 75- -
135	Aicardi syndrome [Neu] 💬 135. Aicardi syndrome × [Neu] Neuromuscular diseases	2 trials    | 0 / 2 / 1 / 0 💬 135. Aicardi syndrome × Some trials have no Phase data.	12 drugs   [ 4 drugs ]	2 genes   37 pathways	12 patients Age distribution💬 135. Aicardi syndrome × Age Num 0-9 1 10-19 3 20-29 5 30-39 2 40-49 1 50-59 - 60-69 - 70-74 - 75- -
136	Hemimegalencephaly [Neu] 💬 "Unilateral megalencephaly" 136. Hemimegalencephaly × [Neu] Neuromuscular diseases	1 trial    | 1 / 1 / 0 / 0 💬 136. Hemimegalencephaly × Some trials have no Phase data.	1 drug   [ - ]	-	27 patients Age distribution💬 136. Hemimegalencephaly × Age Num 0-9 5 10-19 5 20-29 12 30-39 2 40-49 - 50-59 1 60-69 1 70-74 1 75- -
137	Focal cortical dysplasia [Neu] 💬 "FCD" 137. Focal cortical dysplasia × [Neu] Neuromuscular diseases	17 trials    | 3 / 9 / 1 / 0 💬 137. Focal cortical dysplasia × Some trials have no Phase data.	16 drugs   [ 6 drugs ]	8 genes   72 pathways	102 patients Age distribution💬 137. Focal cortical dysplasia × Age Num 0-9 12 10-19 36 20-29 31 30-39 13 40-49 2 50-59 6 60-69 2 70-74 - 75- -
138	Nerve cell migration disorder [Neu] 💬 "Lissencephaly", "Neuronal migration defect", "Neuronal migration disorder", "Lissencephaly", "Ectopic gray matter", "Polymicrogyria", "Cortical dysplasia with cobblestone appearance", "Schizencephaly", "orencephaly", "Miller-Dieker syndrome" 138. Nerve cell migration disorder × [Neu] Neuromuscular diseases	2 trials    | 0 / 2 / 0 / 0 💬 138. Nerve cell migration disorder × Some trials have no Phase data.	4 drugs   [ 2 drugs ]	1 gene   106 pathways	95 patients Age distribution💬 138. Nerve cell migration disorder × Age Num 0-9 3 10-19 8 20-29 55 30-39 13 40-49 11 50-59 4 60-69 - 70-74 - 75- 1
139	Congenital cerebral hypomyelination [Neu] 💬 "Congenital cerebral white matter aplasia", "Congenital hypomyelinating leukodystrophy", "Pelizaeus-Merzbacher disease", "Pelizaeus-Merzbacher-like disease 1", "Pelizaeus-Merzbacher-like disease type 1", "Hypomyelination with atrophy of the basal ganglia and cerebellum", "18q-syndrome", "Chromosome 18q deletion syndrome", "Allan-Herndon-Dudley syndrome", "Mitochondrial Hsp60 chaperonopathy", "Salla disease", "Free sialic acid storage disease", "Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum", "Hypomyelination and congenital cataract", "Ataxia, delayed dentition, and hypomyelination", "Peripheral demyelinating neuropathy", "Central dysmyelinating leukodystrophy", "Waardenburg syndrome", "Hirschsprung disease", "Hirschsprung syndrome" 139. Congenital cerebral hypomyelination × [Neu] Neuromuscular diseases	14 trials    | 3 / 7 / 1 / 0 💬 139. Congenital cerebral hypomyelination × Some trials have no Phase data.	9 drugs   [ 4 drugs ]	2 genes   3 pathways	53 patients Age distribution💬 139. Congenital cerebral hypomyelination × Age Num 0-9 - 10-19 4 20-29 26 30-39 15 40-49 6 50-59 2 60-69 - 70-74 - 75- -
140	Dorabe syndrome [Neu] 💬 "Dravet syndrome" 140. Dorabe syndrome × [Neu] Neuromuscular diseases	145 trials    | 11 / 26 / 93 / 7 💬 140. Dorabe syndrome × Some trials have no Phase data.	74 drugs   [ 16 drugs ]	52 genes   68 pathways	113 patients Age distribution💬 140. Dorabe syndrome × Age Num 0-9 3 10-19 9 20-29 79 30-39 20 40-49 2 50-59 - 60-69 - 70-74 - 75- -
141	Mesial temporal lobe epilepsy with hippocampal sclerosis [Neu] 💬 "Medial temporal lobe epilepsy with hippocampal sclerosis", "Mesial temporal lobe epilepsy with bilateral hippocampal sclerosis", "Medial temporal lobe epilepsy" 141. Mesial temporal lobe epilepsy with hippocampal sclerosis × [Neu] Neuromuscular diseases	-	-	-	82 patients Age distribution💬 141. Mesial temporal lobe epilepsy with hippocampal sclerosis × Age Num 0-9 1 10-19 2 20-29 21 30-39 14 40-49 17 50-59 20 60-69 6 70-74 - 75- 1
142	Myoclonic absence epilepsy [Neu] 💬 "Epilepsy with myoclonic absence" 142. Myoclonic absence epilepsy × [Neu] Neuromuscular diseases	-	-	-	5 patients Age distribution💬 142. Myoclonic absence epilepsy × Age Num 0-9 - 10-19 2 20-29 2 30-39 1 40-49 - 50-59 - 60-69 - 70-74 - 75- -
143	Epilepsy with myoclonic-atonic seizures [Neu] 💬 "Epilepsy with myoclonic cataplexy", "Myoclonic-astatic epilepsy", "Doose syndrome" 143. Epilepsy with myoclonic-atonic seizures × [Neu] Neuromuscular diseases	3 trials    | 0 / 2 / 1 / 0 💬 143. Epilepsy with myoclonic-atonic seizures × Some trials have no Phase data.	4 drugs   [ 1 drug ]	5 genes   11 pathways	17 patients Age distribution💬 143. Epilepsy with myoclonic-atonic seizures × Age Num 0-9 1 10-19 10 20-29 3 30-39 1 40-49 - 50-59 2 60-69 - 70-74 - 75- -
144	Lennox-Gastaut syndrome [Neu] 💬 144. Lennox-Gastaut syndrome × [Neu] Neuromuscular diseases	130 trials    | 2 / 3 / 61 / 1 💬 144. Lennox-Gastaut syndrome × Some trials have no Phase data.	79 drugs   [ 14 drugs ]	51 genes   64 pathways	461 patients Age distribution💬 144. Lennox-Gastaut syndrome × Age Num 0-9 - 10-19 9 20-29 363 30-39 49 40-49 20 50-59 16 60-69 3 70-74 1 75- -
145	West syndrome [Neu] 💬 "Infantile spasm", "Infantile spasms", "Infantile spasms syndrome", "Infantile epileptic spasms", "Infantile epileptic spasms syndrome" 145. West syndrome × [Neu] Neuromuscular diseases	52 trials    | 1 / 19 / 19 / 7 💬 145. West syndrome × Some trials have no Phase data.	64 drugs   [ 19 drugs ]	42 genes   48 pathways	399 patients Age distribution💬 145. West syndrome × Age Num 0-9 15 10-19 9 20-29 352 30-39 21 40-49 2 50-59 - 60-69 - 70-74 - 75- -
146	Ohtahara syndrome [Neu] 💬 "Early infantile epileptic encephalopathy with suppression burst" 146. Ohtahara syndrome × [Neu] Neuromuscular diseases	-	-	-	16 patients Age distribution💬 146. Ohtahara syndrome × Age Num 0-9 6 10-19 2 20-29 7 30-39 1 40-49 - 50-59 - 60-69 - 70-74 - 75- -
147	Early myoclonic encephalopathy [Neu] 💬 147. Early myoclonic encephalopathy × [Neu] Neuromuscular diseases	-	-	-	11 patients Age distribution💬 147. Early myoclonic encephalopathy × Age Num 0-9 6 10-19 1 20-29 3 30-39 1 40-49 - 50-59 - 60-69 - 70-74 - 75- -
148	Epilepsy of infancy with migrating focal seizures [Neu] 💬 "Infant epilepsy with migratory focus seizure", "Migrating partial seizures in infancy", "Infant epilepsy" 148. Epilepsy of infancy with migrating focal seizures × [Neu] Neuromuscular diseases	1 trial    | 1 / 0 / 0 / 0 💬 148. Epilepsy of infancy with migrating focal seizures × Some trials have no Phase data.	1 drug   [ - ]	-	16 patients Age distribution💬 148. Epilepsy of infancy with migrating focal seizures × Age Num 0-9 7 10-19 8 20-29 1 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
149	Hemiconvulsion hemiplegia epilepsy syndrome [Neu] 💬 "One side convulsions", "Hemiplegia", "Epilepsy syndrome" 149. Hemiconvulsion hemiplegia epilepsy syndrome × [Neu] Neuromuscular diseases	55 trials    | 6 / 7 / 10 / 5 💬 149. Hemiconvulsion hemiplegia epilepsy syndrome × Some trials have no Phase data.	61 drugs   [ 17 drugs ]	19 genes   40 pathways	32 patients Age distribution💬 149. Hemiconvulsion hemiplegia epilepsy syndrome × Age Num 0-9 2 10-19 4 20-29 4 30-39 2 40-49 5 50-59 7 60-69 2 70-74 4 75- 2
150	Ring chromosome 20 epilepsy syndrome [Neu] 💬 "Ring chromosome 20 syndrome" 150. Ring chromosome 20 epilepsy syndrome × [Neu] Neuromuscular diseases	-	-	-	11 patients Age distribution💬 150. Ring chromosome 20 epilepsy syndrome × Age Num 0-9 - 10-19 4 20-29 5 30-39 - 40-49 - 50-59 1 60-69 - 70-74 1 75- -
151	Rasmussen encephalitis [Neu] 💬 151. Rasmussen encephalitis × [Neu] Neuromuscular diseases	2 trials    | 0 / 1 / 1 / 0 💬 151. Rasmussen encephalitis × Some trials have no Phase data.	4 drugs   [ 2 drugs ]	6 genes   85 pathways	54 patients Age distribution💬 151. Rasmussen encephalitis × Age Num 0-9 - 10-19 - 20-29 18 30-39 7 40-49 8 50-59 9 60-69 6 70-74 2 75- 4
152	PCDH19-related syndrome [Neu] 💬 "PCDH19-related epilepsy syndrome", "PCDH19 Epilepsy", "Epilepsy and mental retardation limited to females", "PCDH19 female pediatric epilepsy", "PCDH19 related epilepsy", "Protocadherin 19 (PCDH19)-related epilepsy" 152. PCDH19-related syndrome × [Neu] Neuromuscular diseases	10 trials    | 0 / 4 / 5 / 0 💬 152. PCDH19-related syndrome × Some trials have no Phase data.	8 drugs   [ 1 drug ]	16 genes   9 pathways	13 patients Age distribution💬 152. PCDH19-related syndrome × Age Num 0-9 3 10-19 6 20-29 4 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
153	Acute encephalitis with refractory repetitive partial seizures [Neu] 💬 "AERRPS", "Refractory frequent partial seizures intussusception acute encephalitis", "Febrile infection related epilepsy syndrome", "FIRES", "New onset refractory status epilepsy syndrome", "NORSE syndrome" 153. Acute encephalitis with refractory repetitive partial seizures × [Neu] Neuromuscular diseases	3 trials    | 0 / 0 / 0 / 0 💬 153. Acute encephalitis with refractory repetitive partial seizures × Some trials have no Phase data.	3 drugs   [ 2 drugs ]	3 genes   22 pathways	84 patients Age distribution💬 153. Acute encephalitis with refractory repetitive partial seizures × Age Num 0-9 - 10-19 3 20-29 43 30-39 15 40-49 12 50-59 5 60-69 4 70-74 2 75- -
154	Epilepsy with continuous spikes and waves during slow sleep [Neu] 💬 "Epileptic encephalopathy with continuous spike-and-wave during sleep", "Rolandic epilepsy, mental retardation, and speech dyspraxia" 154. Epilepsy with continuous spikes and waves during slow sleep × [Neu] Neuromuscular diseases	8 trials    | 0 / 8 / 0 / 0 💬 154. Epilepsy with continuous spikes and waves during slow sleep × Some trials have no Phase data.	3 drugs   [ 1 drug ]	-	13 patients Age distribution💬 154. Epilepsy with continuous spikes and waves during slow sleep × Age Num 0-9 1 10-19 9 20-29 3 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
155	Acquired aphasia with convulsive disorder [Neu] 💬 "Landau-Kleffner syndrome" 155. Acquired aphasia with convulsive disorder × [Neu] Neuromuscular diseases	1 trial    | 0 / 1 / 1 / 0 💬 155. Acquired aphasia with convulsive disorder × Some trials have no Phase data.	2 drugs   [ 2 drugs ]	29 genes   15 pathways	4 patients Age distribution💬 155. Acquired aphasia with convulsive disorder × Age Num 0-9 1 10-19 2 20-29 1 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
156	Rett syndrome [Neu] 💬 156. Rett syndrome × [Neu] Neuromuscular diseases	63 trials    | 6 / 30 / 25 / 0 💬 156. Rett syndrome × Some trials have no Phase data.	79 drugs   [ 29 drugs ]	100 genes   116 pathways	136 patients Age distribution💬 156. Rett syndrome × Age Num 0-9 1 10-19 5 20-29 102 30-39 20 40-49 7 50-59 1 60-69 - 70-74 - 75- -
157	Sturge-Weber syndrome [Neu] 💬 "Síndrome de Sturge-Weber" 157. Sturge-Weber syndrome × [Neu] Neuromuscular diseases	11 trials    | 3 / 7 / 1 / 1 💬 157. Sturge-Weber syndrome × Some trials have no Phase data.	14 drugs   [ 4 drugs ]	5 genes   66 pathways	91 patients Age distribution💬 157. Sturge-Weber syndrome × Age Num 0-9 2 10-19 7 20-29 23 30-39 18 40-49 13 50-59 16 60-69 7 70-74 3 75- 2
158	Tuberous sclerosis [Neu] 💬 "Tuberous sclerosis complex", "TSC" 158. Tuberous sclerosis × [Neu] Neuromuscular diseases	132 trials    | 5 / 35 / 57 / 10 💬 158. Tuberous sclerosis × Some trials have no Phase data.	91 drugs   [ 22 drugs ]	41 genes   119 pathways	1,165 patients Age distribution💬 158. Tuberous sclerosis × Age Num 0-9 2 10-19 29 20-29 394 30-39 260 40-49 230 50-59 170 60-69 55 70-74 18 75- 7
177	Joubert syndrome related disorder [Neu] 💬 "Joubert syndrome and related disorder", "Joubert syndrome", "JSRD", "Arima syndrome", "Senior-Loken syndrome", "Senior-Løken syndrome", "COACH syndrome", "Orofaciodigital syndrome" 177. Joubert syndrome related disorder × [Neu] Neuromuscular diseases	2 trials    | 0 / 0 / 0 / 0 💬 177. Joubert syndrome related disorder × Some trials have no Phase data.	4 drugs   [ 1 drug ]	-	27 patients Age distribution💬 177. Joubert syndrome related disorder × Age Num 0-9 2 10-19 4 20-29 17 30-39 2 40-49 1 50-59 1 60-69 - 70-74 - 75- -
201	Angelman syndrome [Neu] 💬 201. Angelman syndrome × [Neu] Neuromuscular diseases	40 trials    | 15 / 14 / 11 / 0 💬 201. Angelman syndrome × Some trials have no Phase data.	48 drugs   [ 11 drugs ]	22 genes   22 pathways	38 patients Age distribution💬 201. Angelman syndrome × Age Num 0-9 - 10-19 3 20-29 20 30-39 13 40-49 2 50-59 - 60-69 - 70-74 - 75- -
263	Cerebrotendinous xanthomatosis [Neu] 💬 "CTX", "27-hydroxylase deficiency", "CYP27 deficiency" 263. Cerebrotendinous xanthomatosis × [Neu] Neuromuscular diseases	10 trials    | 1 / 1 / 3 / 0 💬 263. Cerebrotendinous xanthomatosis × Some trials have no Phase data.	12 drugs   [ 2 drugs ]	2 genes   3 pathways	58 patients Age distribution💬 263. Cerebrotendinous xanthomatosis × Age Num 0-9 - 10-19 - 20-29 1 30-39 3 40-49 10 50-59 23 60-69 15 70-74 3 75- 3
307	Canavan disease [Neu] 💬 307. Canavan disease × [Neu] Neuromuscular diseases	6 trials    | 3 / 3 / 0 / 0 💬 307. Canavan disease × Some trials have no Phase data.	10 drugs   [ 3 drugs ]	2 genes   2 pathways	-
308	Progressive leukoencephalopathy [Neu] 💬 "Megalencephalic leukoencephalopathy with subcortical cyst", "Leukoencephalopathy with vanishing white matter", "Vanishing white matter disease", "Leukoencephalopathy, progressive, with ovarian failure" 308. Progressive leukoencephalopathy × [Neu] Neuromuscular diseases	4 trials    | 1 / 1 / 0 / 0 💬 308. Progressive leukoencephalopathy × Some trials have no Phase data.	4 drugs   [ 1 drug ]	5 genes   2 pathways	32 patients Age distribution💬 308. Progressive leukoencephalopathy × Age Num 0-9 - 10-19 - 20-29 1 30-39 3 40-49 7 50-59 2 60-69 12 70-74 4 75- 3
309	Progressive myoclonus epilepsy [Neu] 💬 "Progressive myoclonic epilepsy", "Unverricht-Lundborg disease", "Lafora disease", "Benign adult familial myoclonus epilepsy", "BAFME" 309. Progressive myoclonus epilepsy × [Neu] Neuromuscular diseases	16 trials    | 2 / 3 / 7 / 0 💬 309. Progressive myoclonus epilepsy × Some trials have no Phase data.	26 drugs   [ 5 drugs ]	6 genes   14 pathways	52 patients Age distribution💬 309. Progressive myoclonus epilepsy × Age Num 0-9 - 10-19 - 20-29 6 30-39 11 40-49 8 50-59 10 60-69 7 70-74 3 75- 7
320	Inherited glycosylphosphatidylinositol deficiency [Neu] 💬 "Inherited GPI deficiency", "IGD", "Congenital glycosylphosphatidylinositol deficiency", "Congenital GPI deficiency", "Autosomal recessive mental retardation-42", "MRT42" 320. Inherited glycosylphosphatidylinositol deficiency × [Neu] Neuromuscular diseases	3 trials    | 0 / 0 / 0 / 0 💬 320. Inherited glycosylphosphatidylinositol deficiency × Some trials have no Phase data.	1 drug   [ 1 drug ]	-	2 patients Age distribution💬 320. Inherited glycosylphosphatidylinositol deficiency × Age Num 0-9 - 10-19 - 20-29 2 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
334	Cerebral creatine deficiency syndrome [Neu] 💬 "CCDS" 334. Cerebral creatine deficiency syndrome × [Neu] Neuromuscular diseases	-	-	-	1 patient Age distribution💬 334. Cerebral creatine deficiency syndrome × Age Num 0-9 - 10-19 1 20-29 - 30-39 - 40-49 - 50-59 - 60-69 - 70-74 - 75- -
342	LMNB1-related cerebral leukoencephalopathy [Neu] 💬 "Autosomal dominant adult-onset demyelinating leukodystrophy", "LMNB1-related autosomal dominant leukodystrophy", "ADLD" 342. LMNB1-related cerebral leukoencephalopathy × [Neu] Neuromuscular diseases	-	-	-	-
343	PURA-related neurodevelopmental disorders [Neu] 💬 "PURA-NDDs" 343. PURA-related neurodevelopmental disorders × [Neu] Neuromuscular diseases	-	-	-	-
348	Lowe syndrome [Neu] 💬 "Oculocerebrorenal syndrome of Lowe", "OCRL" 348. Lowe syndrome × [Neu] Neuromuscular diseases	2 trials    | 0 / 1 / 0 / 0 💬 348. Lowe syndrome × Some trials have no Phase data.	2 drugs   [ 1 drug ]	1 gene   4 pathways	-